Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates
Access the video here
BOSTON and LONDON – May 29, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an
oncology biotechnology company developing novel payload antibody drug conjugates
(ADCs), today announced the release of a “Meet the Team” video featuring newly
appointed Mark F. Kubik, Head of Business Development – Oncology.
The video is now available on the Presentations page under the Investors section of the
Company’s website (www.akaritx.com).
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation
spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC
discovery platform, the Company has the ability togenerate ADC candidates and
optimize them based on the desired application to any target of interest. Akari’s lead
candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary
linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that
use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel
payload that is a spliceosome inhibitor designed to disrupt RNA splicing within cancer
cells. This splicing inhibition has been shown in preclinical animal models to induce
cancer cell death while activating immune cells to drive robust and durable activity. In
preclinical studies, AKTX-101 has shown to have significant activity and prolonged
survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the
potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged
survival as both a single agent and in combination with checkpoint inhibitors, as
compared to appropriate controls. The Company is generating validating data on its
novel payload PH1 to continue advancing its lead asset, as well as other undisclosed
targets with this novel payload.
For more information about the Company, please visit www.akaritx.com and connect on
X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, about the Company that involve
risks and uncertainties relating to future events and the future performance of the
Company. Actual events or results may differ materially from these forward-looking
statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,”
“future,” “opportunity” “will likely result,” “target,” variations of such words, and similar
expressions or negatives of these words are intended to identify such forward-looking
statements, although not all forward-looking statements contain these identifying words.
Examples of such forward-looking statements include, but are not limited to, express or
implied statements regarding the ability of the Company to advance its product
candidates for the treatment of cancer and any other diseases, and ultimately bring
therapies to patients; the Company’s targets, plans, objectives or goals for future
operations, including those related to its product candidates; financial projections; future
economic performance; and the assumptions underlying or relating to such statements.
These statements are based on the Company’s current plans, estimates and
projections. By their very nature, forward-looking statements involve inherent risks and
uncertainties, both general and specific. A number of important factors, including those
described in this communication, could cause actual results to differ materially from
those contemplated in any forward-looking statements. Factors that may affect future
results and may cause these forward-looking statements to be inaccurate include,
without limitation: the potential impact of unforeseen liabilities, future capital
expenditures, revenues, costs, expenses, earnings, synergies, economic performance,
indebtedness, financial condition and losses on the future prospects, business and
management strategies for the management, expansion and growth of the business;
risks related to global as well as local political and economic conditions, including
interest rate and currency exchange rate fluctuations; potential delays or failures related
to research and/or development of the Company’s programs or product candidates;
risks related to any loss of the Company’s patents or other intellectual property rights;
any interruptions of the supply chain for raw materials or manufacturing for the
Company’s product candidates, including as a result of potential tariffs; the nature,
timing, cost and possible success and therapeutic applications of product candidates
being developed by the Company and/or its collaborators or licensees; the extent to
which the results from the research and development programs conducted by the
Company, and/or its collaborators or licensees may be replicated in other studies and/or
lead to advancement of product candidates to clinical trials, therapeutic applications, or
regulatory approval; uncertainty of the utilization, market acceptance, and commercial
success of the Company’s product candidates; risks related to competition for the
Company’s product candidates; and the Company’s ability to successfully develop or
commercialize its product candidates. While the foregoing list of factors presented here
is considered representative, no list should be considered to be a complete statement of
all potential risks and uncertainties. More detailed information about the Company and
the risk factors that may affect the realization of forward-looking statements is set forth
in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s
website at www.sec.gov. The Company assumes no, and hereby disclaims any,
obligation to update the forward-looking statements contained in this press release
except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
